Compare BridgeBio Pharma Inc (BBIO) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Freshworks Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Freshworks Inc trades at $11.97 (market cap $3.31B). The key difference: BridgeBio Pharma Inc is far larger — about 5× Freshworks Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Freshworks Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | FRSH | |
|---|---|---|
Market Cap | $16.61B | $3.31B |
Sector | Health | Technology |
52-Week High | $90.17 | $13.97 |
52-Week Low | $47.29 | $6.88 |
Enterprise Value | $18.16B | $2.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Freshworks (FRSH) trades at $11.84, up 2.16% today, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $0.17 versus $0.13 expected, and revenue growth of 16% year-over-year. Recent developments include FedRAMP 'In-Process' status for Freshservice and a leadership appointment, reinforcing its competitive position in AI-powered service operations.
The stock offers upside to the $16.50 consensus price target, driven by robust fundamentals like a 20.49% net margin and 19.7% ROE. Risks include high EV/EBITDA valuation and dependence on SaaS sector growth. Analysts are evenly split between Buy and Hold ratings, indicating cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
